In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report), with a price target of $20.00.

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...

China-based GDS Holdings (GDS) is surging 6% after investment bank TD Cowen raised its price target on the shares. The ...

TD Cowen has downgraded Merck (NYSE:MRK) to hold from buy, citing Keytruda's impending loss of market exclusivity, or LOE. The bank said it no longer sees "viable arguments" for outperformance in the ...

Shares of Merck & Co. Inc. fell more than 0.5% on Monday afternoon, tracking their fifth consecutive decline in the worst ...

The New Hampshire-based company is opening new gyms around the country, spurred by a CEO change that has helped propel its ...

On Sunday, Trump said he would instruct the Treasury to stop minting pennies, calling the process wasteful. In particular, he flagged in a social media post that producing pennies "literally" costs ...

To come up with last week’s worst performers, we considered only the stocks with at least $2 billion in market capitalization ...

Liam Griffin, long one of the pillars of Irvine’s tech scene, will be leaving chipmaker Skyworks Solutions Inc., yielding the ...

Logistics Management Group News Editor Jeff Berman recently interviewed Jason Seidl, Managing Director, Industrials - ...